Who is sponsoring NCT04210557?

NCT04210557 is sponsored by Yale University.

What drugs are being tested in NCT04210557?

Interventions in NCT04210557: Transcranial Magnetic Stimulation (TMS).

What condition does NCT04210557 study?

NCT04210557 studies Schizophrenia, Schizo Affective Disorder, Auditory Hallucination.

Is NCT04210557 still recruiting?

NCT04210557 is currently terminated. Last updated 1 August 2024.

Are results published for NCT04210557?

Yes — primary outcome results have been posted to ClinicalTrials.gov. See the outcomes section above for details.

Last reviewed 2024-08-01 · How we verify

NCT04210557

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Models of Auditory Hallucination

Terminated NA Results posted Last updated 1 August 2024

What this trial tests

NA trial testing Transcranial Magnetic Stimulation (TMS) in Schizophrenia in 1 participant. Terminated before completion.

Timeline

27 February 2020

Primary endpoint
1 April 2021

1 April 2021

Quick facts

Lead sponsor	Yale University
Phase	NA
Status	Terminated
Study type	INTERVENTIONAL
Allocation	randomized
Design	parallel
Masking	double
Primary purpose	basic science
Enrollment	1
Start date	27 February 2020
Primary completion	1 April 2021
Estimated completion	1 April 2021
Sites	1 location across United States

Drugs / interventions tested

Transcranial Magnetic Stimulation (TMS)

Conditions studied

Schizophrenia — all drugs for Schizophrenia →
Schizo Affective Disorder — all drugs for Schizo Affective Disorder →
Auditory Hallucination — all drugs for Auditory Hallucination →

Sponsor

Yale University

Who can join

Adults 18 to 45, any sex, with Schizophrenia or Schizo Affective Disorder. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

The purpose of this study is to address the shortcoming in clinical hallucination research by causally manipulating the neural loci of conditioned hallucination task behavior in-person in patients with psychosis using transcranial magnetic stimulation (TMS), tracking the impact of this manipulation on the number of times participants with hallucinations report hearing tones that were not presented. With such a causal intervention, the veracity of this explanation of hallucinations will be either validated or disconfirmed. If validated, the task can be further developed as a biomarker for predicting the hallucination onset, guiding, developing or tracking the effects of treatments for hallucinations.

Publications & conference data

No peer-reviewed publications indexed yet for this trial.

Verify or expand the search:

Other trials of Transcranial Magnetic Stimulation (TMS)

Trials testing the same drug.

NCT05861284 — Developing and Optimizing Transcranial Magnetic Stimulation for Motor Rehabilitation · NA · withdrawn
NCT07250464 — Motor Evoked Potential and Cortical Silent Period in Migraine · NA · not yet recruiting
NCT07110493 — Study of Visual Perception Phenomena: Phosphene Mapping Induced by TMS and Its Relationship With Eye Movements · NA · recruiting
NCT06960083 — Transcranial Magnetic Stimulation in Misophonia · NA · recruiting
NCT07179406 — The Effect of Spinal Cord Stimulators on Restless Leg Syndrome · NA · recruiting

Other recruiting trials for Schizophrenia

Currently open trials in the same condition.

NCT07424404 — A Study to Evaluate the Long-term Safety and Tolerability of KarXT and KarX-EC for the Treatment of Schizophrenia and Au · Phase 3 · recruiting
NCT07467993 — Study to Assess the Safety, Tolerability, and Treatment Response of GXV813 in Hospitalized Adults With Schizophrenia · Phase 2 · recruiting
NCT07379827 — Effectiveness and Adverse-effect Switch Evaluation of Xanomeline and Trospium Chloride (KarXT) · recruiting
NCT06758414 — CBT-CP for Veterans With SMI · NA · recruiting
NCT07395206 — Acceptability, Feasibility and Preliminary Outcomes of the Kiso Mind App for Outpatients With Schizophrenia Spectrum Dis · NA · recruiting

Other Yale University trials

Trials by the same sponsor.

NCT06900998 — Pilot Study: Effects of Nimodipine on Alcohol Drinking · Phase 2 · not yet recruiting
NCT04910984 — Developing a Chatbot to Promote HIV Testing · NA · not yet recruiting
NCT07458087 — Accuracy of the Accuro 3S · NA · not yet recruiting
NCT07398404 — A Multiple Health Behavior Change (MHBC) Intervention for Weight Loss and Smoking Cessation for Pre-Bariatric Surgery Pa · Phase 1, PHASE2 · not yet recruiting
NCT07305324 — Improving Liver Fibrosis Diagnosis in Primary Care Using FibroX AI · NA · not yet recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT04210557 (US National Library of Medicine, public domain)
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Yale University
Last refreshed: 1 August 2024

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT04210557.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing